Merck, Glenmark Stifled Cholesterol Drug Market, Suit Says
Named plaintiff FWK Holdings Inc. said in its antitrust suit that Merck paid Glenmark to stay out of the market with a generic version of its blockbuster drug between December 2011 and December 2016.
The deal was reached to settle a patent lawsuit that...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login